单位：[1]Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属同济医院[3]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China河南省肿瘤医院[4]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China四川大学华西医院[5]Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China[6]Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou, Peoples R China[7]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属协和医院[8]Zhe Jiang Med Univ, Hosp Affiliated 1, Hangzhou, Zhejiang, Peoples R China[9]Peking Univ, Peoples Hosp, Inst Hematol, Beijing, Peoples R China[10]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[11]China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China[12]Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China[13]Fourth Mil Med Univ, Tangdu Hosp, Xian, Shaanxi, Peoples R China[14]Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China[15]Northern Jiangsu Peoples Hosp, Yangzhou, Jiangsu, Peoples R China[16]Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China[17]Jiangsu Hansoh Pharmaceut, Lianyuangang, Jiangsu, Peoples R China
Li Zhang,Meng Li,Zhang Yanli,et al.Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):
APA：
Li, Zhang,Meng, Li,Zhang, Yanli,Zhu, Huanling,Cui, Jiuwei...&Wang, Jianxiang.(2019).Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study.JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA：
Li, Zhang,et al."Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)
医学